Mid-Study RTSM Migration: How To Switch Vendors Without Disrupting Your Trial

By Chuck Harris, founder and COO, Korio

In the high-stakes environment of clinical research, an underperforming Randomization and Trial Supply Management (RTSM) system is more than a technical hurdle—it is a direct threat to study integrity and timelines. While switching providers mid-study was once considered a last resort, modern migration methodologies have transformed this transition into a viable strategic pivot.

The decision to change often hinges on three critical indicators: declining vendor responsiveness, functional gaps that force teams into risky manual workarounds, and recurring quality issues that jeopardize data. By leveraging contemporary platforms with pre-validated migration toolkits and specialized data reconciliation processes, sponsors can now transition active studies without disrupting site operations. If a trial has years remaining and the technical debt of the current system is mounting, a structured mid-study migration offers a documented, low-risk path to reclaiming control over study quality and operational efficiency.